April 23, 2024 Spyre Therapeutics, Inc. Waltham, MA 02453 Attention: Scott Burrows Re: 3(a)(9) Exchange Agreement Ladies and Gentlemen:3(a)(9) Exchange Agreement • April 25th, 2024 • Spyre Therapeutics, Inc. • Pharmaceutical preparations
This letter agreement (the “Agreement”) confirms the agreement of Spyre Therapeutics, Inc. (the “Company”), and the holder of the Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share, of the Company (the “Series A Preferred Stock”) listed on Schedule I attached hereto (the “Stockholder”), pursuant to which the Stockholder has agreed to exchange 90,992 shares (the “Preferred Shares”) of Series A Preferred Stock, beneficially owned or owned of record, as applicable, by the Stockholder, in consideration for a total of 3,639,680 shares (the “Common Shares”) of Common Stock, par value $0.0001 per share, of the Company.
